Skip to main content
OpenTrials

Clinical trial condition

Recurrence

Explore clinical trials studying Recurrence. Study availability and eligibility vary by location and protocol.

2,310 public trials 520 recruiting studies
Refine in advanced search Browse all conditions

Recurrence trial results

Completed

BIBF 1120 for Recurrent High-Grade Gliomas

NCT01380782

Conditions
Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma, +23 more
Locations
  • Massachusetts General Hospital Boston, Massachusetts, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • Cleveland Clinic Cleveland, Ohio, United States
  • University of Virginia Charlottesville, Virginia, United States
View Trial Details
Completed

Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif® New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting.

NCT01101776

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +8 more
Locations
  • Merck Serono Research Site Bruce, Australian Capital Territory, Australia
  • Merck Serono Research Site Burwood, New South Wales, Australia
  • Merck Serono Research Site Chatswood, New South Wales, Australia
  • Merck Serono Research Site Orange, New South Wales, Australia
View all 16 locations
View Trial Details
Completed

Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Hodgkin's or Non-Hodgkin's Lymphoma

NCT00002941

Conditions
Burkitt Lymphoma, DNA Virus Infections, Dendritic Cell Sarcoma, Interdigitating, +22 more
Locations
  • University of Alabama at Birmingham Comprehensive Cancer Center Birmingham, Alabama, United States
  • University of South Alabama Medical Center Mobile, Alabama, United States
  • Phoenix Children's Hospital Phoenix, Arizona, United States
  • Arizona Cancer Center Tucson, Arizona, United States
View all 235 locations
View Trial Details
Completed

A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Malignant Glioma

NCT00539344

Conditions
Astrocytoma, Disease Attributes, Glioblastoma, +13 more
Locations
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
  • Henry Ford Health System Detroit, Michigan, United States
  • Irving Comprehensive Cancer Center, Columbia University Medical Center New York, United States
  • University of Texas, MD Anderson Cancer Center Houston, Texas, United States
View Trial Details
Completed

Study to Evaluate the Safety and Efficacy of Adeno-IFN Gamma in Cutaneous B-cell Lymphoma

NCT00394693

Conditions
Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +11 more
Locations
  • Stanford University School of Medicine Stanford, California, United States
  • Northwestern University Medical School Chicago, Illinois, United States
  • M.D. Anderson Cancer Center Houston, Texas, United States
  • Hopital Lapeyronie Montpellier, France
View Trial Details
Completed

AZD1152 in Diffuse Large B-cell Lymphoma

NCT01354392

Conditions
Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • Christie NHS Foundation Trust (Christie Hospital) Machester, Lancashire, United Kingdom
  • Oxford Radcliffe NHS Trust (Cancer & Haematology Centre, Churchill Hospital) Oxford, Oxfordshire, United Kingdom
View Trial Details

Related conditions